Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TIRmed Pharma
Bromma, Swedentirmedpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TIRmed Pharma’s lead program is a novel, non-steroid topical cream for mild to moderate atopic dermatitis. The product candidate, a chemically stabilized single-stranded oligonucleotide, has shown anti-inflammatory and anti-pruritic effects in preclinical models. It acts by modulating immune responses without broad immunosuppression. Proof-of-concept studies have demonstrated local efficacy in animal models; clinical development preparations are ongoing with recent funding secured for further advancement.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Synthetic oligonucleotideSmall molecule (as the compound is a chemically stabilized, single-stranded oligonucleotide)
- Industry
- Biotech
02
Partnerships
EU-funded Fight-nCoV project for antiviral nasal spray development
Beyond the preview
Go deeper on TIRmed Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIRmed Pharma.